CGIX Cancer Genetics Inc

CANCER GENETICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Cancer Genetics, Inc. To Contact The Firm

NEW YORK--(BUSINESS WIRE)--

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) (NASDAQ:CGIX).

If you invested in Cancer Genetics stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/CGIX. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

EN
06/04/2018

Underlying

CGIXCancer Genetics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cancer Genetics Inc

 PRESS RELEASE
Free
CGIX Cancer Genetics...

Vyant Bio Provides Update on Winddown Activities

Vyant Bio Provides Update on Winddown Activities CHERRY HILL, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio’s Board of Directors currently anticipates that it will file a Certificate of Dissolution with the State of Delaware in late December 2023, after which the Company’s common stock will cease to trade and holders of shares of the Company’s common sto...

November 10, 2023 1 EN
 PRESS RELEASE
Free
CGIX Cancer Genetics...

Vyant Bio Announces Stockholder Approval of Plan of Dissolution

Vyant Bio Announces Stockholder Approval of Plan of Dissolution CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the “Special Meeting”). At the Special Meeting, Vyant Bio’s stockholders, upon the unanimous recommendation of Vyant Bio’s board of directors, voted in favor of the proposal to approve the voluntary liquidation and dissolution of the Company, pursuant to a Plan of Liquidation and Dissolution (the “Dissolution Proposal). The proposal r...

November 1, 2023 1 EN
 PRESS RELEASE
Free
CGIX Cancer Genetics...

Vyant Bio Announces Completion of StemoniX Asset Sale

Vyant Bio Announces Completion of StemoniX Asset Sale CHERRY HILL, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that it has completed the sale of all or substantially all of the assets of the Company (the “Sale”) pursuant to an Asset Purchase Agreement dated July 13, 2023. ABOUT VYANT BIO, INC. Vyant Bio, Inc. (OTC: VYNT) has no continuing operating activities other than the winddown and closure of its business. The Company is currently seeking to obtain its shareholders’ approval for the voluntary liquidation and dissolution o...

October 24, 2023 1 EN
 PRESS RELEASE
Free
CGIX Cancer Genetics...

Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,11...

Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders CHERRY HILL, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that its special meeting of stockholders on October 19, 2023 (the “Special Meeting”) was reconvened resulting in the approval of the sale of all or substantially all of the assets of the Company. At the Special Meeting, Vyant Bio’s stockholders, upon the unanimous recommendation of Vyant Bio’s board of ...

October 19, 2023 1 EN
 PRESS RELEASE
Free
CGIX Cancer Genetics...

Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,...

Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the “Special Meeting”) was reconvened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals as described in the Company’s definitive proxy statement filed...

October 11, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch